Relay Therapeutics, Inc.
RLAY
주식 순위
#4162
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
주가
$17.72
시가총액
$3.88B
변동 (1일)
3.70%
변동 (1년)
148.21%
국가
US
거래 Relay Therapeutics, Inc. (RLAY)
카테고리
Healthcare
Relay Therapeutics, Inc. (RLAY)의 발행 주식 수
June 2026 기준 발행 주식 수: 202.85M
Relay Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 202.85M입니다. December 2023 말 기준 회사는 122.58M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Relay Therapeutics, Inc. (RLAY)의 발행 주식 수 기록 (2018 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 202.85M | 41.98% |
| 2024 | 142.87M | 16.55% |
| 2023 | 122.58M | 9.22% |
| 2022 | 112.23M | 17.97% |
| 2021 | 95.14M | 5.65% |
| 2020 | 90.05M | 2,003.45% |
| 2019 | 4.28M | 72.27% |
| 2018 | 2.49M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 25.17% |
US
|
|
| 396.00M | 95.22% |
US
|
|
| 478.91M | 136.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -69.34% |
NL
|
